Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Cerebral Toxoplasmosis and AIDS (TOXODFA)

This study has been completed.
Information provided by (Responsible Party):
University Hospital, Limoges Identifier:
First received: December 2, 2008
Last updated: March 22, 2014
Last verified: December 2013

With a HIV incidence much higher in the DFA than in European French territory, this disease is a major public health problem in these areas, especially in French Guiana.

Cerebral toxoplasmosis is a priority among the opportunistic infections in AIDS patients from the DFA because of its frequency (French West Indies) and of its lethality (French Guiana).

The diagnosis of cerebral toxoplasmosis may be difficult because based only on presumptive clinical and radiological features. The response to specific antitoxoplasmic therapy confirms a posteriori the diagnosis.

In reference to the data collected by the Biological Resource Centre Toxoplasma, in particular in French Guiana, we think that T. gondii strains reactivating in AIDS patients from DFA are genetically different from those reactivating in AIDS patients from Europe, with an increased capacity for dissemination via peripheral blood in the first ones. This more frequent or more prolonged parasitemia could facilitate the diagnosis of cerebral toxoplasmosis by PCR test from peripheral blood samples in AIDS patients from the French departments of America.

Condition Intervention
Cerebral Toxoplasmosis
Other: Toxoplasma PCR assay

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Cerebral Toxoplasmosis and AIDS in the French Departments of America (DFA). Diagnostic Contribution of a PCR Assay and Genetic Diversity of Toxoplasma Gondii.

Resource links provided by NLM:

Further study details as provided by University Hospital, Limoges:

Secondary Outcome Measures:
  • Isolation, genetic typing and storage of T. gondii strains collected among AIDS patients with cerebral toxoplasmosis from the DFA. [ Time Frame: 3 years ]

Enrollment: 46
Study Start Date: June 2009
Study Completion Date: December 2013
Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Intervention Details:
    Other: Toxoplasma PCR assay
    Toxoplasma PCR assay

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
AIDS patients from the French West Indies and French Guiana having clinical and radiological suspicion of cerebral toxoplasmosis

Inclusion Criteria:

  • Adult patient (> 18 years)
  • Patient being informed and accepting to participate in the study with signature of informed consent
  • HIV positive serology
  • Clinical and radiological suspicion of cerebral toxoplasmosis justifying the start of specific antitoxoplasmic therapy

Exclusion Criteria:

  • Protected patient
  • Patient uncovered by social insurance
  • Specific antitoxoplasmic therapy already initiated since 72h or more
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00803621

Service des Maladies Infectieuses - CHU de Pointe à Pitre
Pointe à Pitre, Guadeloupe, France
Services Maladies Infectieuses et Tropicales- CHU Fort-de-France
Fort-de-France, France
Dermatologie et CISIH- CH Andrée Rosemon
Guyane-Française, France
Maladies Infectieuses et Tropicales - CH Andrée Rosemon
Guyane-Française, France
Médecine- CH Ouest Guyanais
Guyane-Français, France
Sponsors and Collaborators
University Hospital, Limoges
Study Director: Daniel AJZENBERG, PharmD, PhD CHU Limoges
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: University Hospital, Limoges Identifier: NCT00803621     History of Changes
Other Study ID Numbers: I07009
Study First Received: December 2, 2008
Last Updated: March 22, 2014

Additional relevant MeSH terms:
Toxoplasmosis, Cerebral
Protozoan Infections
Parasitic Diseases
Brain Abscess
Central Nervous System Protozoal Infections
Central Nervous System Parasitic Infections
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Central Nervous System Infections processed this record on April 25, 2017